AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comNOV 42 min read$ALMR

Alamar Biosciences Q3 Earnings Call Highlights

Alamar Biosciences (ALMR) reported Q3 earnings, with revenue up 64% YoY. Key projects include UK Biobank work and a GSK partnership. Biopharma customers now represent 49% of revenue. Gross profit rose to $20.6M, but operating loss widened to $15.1M. The company raised its 2026 revenue guidance to $121M-$123M. ALMR plans to submit its ARGO HT/DX clinical instrument for FDA approval by late 2027.

Original reporting
finance.yahoo.com
Published Nov 4, 2026, 12:14 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 12:21 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Alamar Biosciences Q3 Earnings Call Highlights — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$ALMRNeutralMed
01

Why it matters

The raised guidance reflects strong biopharma demand, but operating loss widening signals cost pressures; investors will assess net effect on valuation.

02

Market read

Earnings and guidance update for a small‑cap biotech; relevant for sector‑focused traders and investors tracking proteomics market growth.

03

What to watch

The upcoming UK Biobank sample processing start in Q4 and the GSK partnership may take time to translate into revenue.

Relevance 7/10Novelty 7/10Timing: immediate post‑earnings release

Background

Alamar Biosciences (NASDAQ:ALMR) provides high‑sensitivity proteomics platforms for research and clinical applications.

Company-level read

Ticker impact

$ALMRNeutralHigh confidence
Context

Alamar Biosciences raised its full-year 2026 revenue guidance to $121‑$123 million and reported Q3 gross profit of $20.6 million, a primary earnings disclosure.

Expected impact

potential modest upside as market prices in higher revenue outlook, offset by expense increase

Evidence & confidence

New guidance is material and first reported; investors will weigh higher revenue against rising costs.

Market effects

Sector

Positive signal for proteomics and biotech services sector as Alamar's biopharma customer share grows.

Regional

U.S. biotech investors may see modest reallocation toward Alamar and similar small‑cap life‑science firms.

Global

Limited to niche proteomics market; no broad macro impact.

Counterpoint

What could challenge this read

Higher expenses and a sequential TAP revenue decline could pressure margins, making the stock vulnerable to a pullback.

Key entities

  • company
    Alamar Biosciences

    Life‑sciences firm developing multiplexed immunoassay technology.

  • company
    GSK

    Pharmaceutical partner collaborating on a large serum‑sample study.

Read at source← All news

StoryAlamar Biosciences reports Q3 profit surge and lifts full‑year revenue outlook

Also covered by

1 outlet

Related articles

NOV 3
Med

Alamar Q3 2026 presentation: consumables surge, guidance raised

Alamar Biosciences reported Q3 2026 revenue of $33.5M, up 68% YoY, driven by a 79% surge in consumables sales. The company raised its full-year outlook, citing strong biopharma customer demand and research partnerships. Gross margin improved to 61.5%, but net loss widened to $13.3M due to increased operating expenses. The stock closed at $30.22, up 4.42%, before slipping in after-hours trading.

investing.com2 min
NOV 3
$ALMRMed

Alamar Biosciences Reports Third Quarter 2026 Financial Results and Raises 2026 Revenue Guidance

Alamar Biosciences, Inc. (ALMR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Alamar Biosciences Reports Third Quarter 2026 Financial Results and Raises 2026 Revenue Guidance FREMONT, Calif. Nov. 03, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection o

SEC EDGAR 8-K2 min
OCT 29
$ALMRLow

Alamar Biosciences' Protein Signature Detects ALS With 98.3% Accuracy In Study

Alamar Biosciences (ALMR) reported that Emory University researchers used its NULISA tech to identify a 10-protein blood signature with 98.3% accuracy in detecting ALS. The study, published in Nature Communications, involved 632 ALS patients and 160 healthy controls for development, and 144 ALS patients and 37 healthy controls for validation. The signature outperformed the established NFL biomarker. ALMR's stock closed at $34.30, up 7.42%, and was at $34.15 in overnight trading.

rttnews.com2 min
OCT 28
$ALMRMedAI 8/10

Alamar Biosciences’ technology used in study detecting ALS with 98% accuracy

Alamar Biosciences (ALMR) reported that Emory University researchers used its NULISA technology to identify a 10-protein blood signature with 98.3% accuracy in detecting ALS. The study, published in Nature Communications, measured over 300 proteins, though the signature is not yet clinically validated. CEO Yuling Luo emphasized the importance of measuring low-abundance proteins.

tipranks.com1 min
AUG 18
$ALMRMedAI 8/10

Alamar Biosciences (ALMR) Q2 2026 Earnings Call Transcript

Alamar Biosciences (ALMR) reported Q2 2026 revenue of $29.4M, up 82% YoY, with gross margin at 60%. Consumables rose 147% to $15.5M and instrument revenue rose 35% to $7.8M. Net loss was $13.2M. Cash was $256.3M. Full-year 2026 revenue guidance is $116M to $120M and management targets 100+ new instruments.

fool.com7 min